https://orcid.org/0000-0002-1886-2624
Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Rachel H. Rose, Armin Sepp, Felix Stader, Katherine L. Gill, Cong Liu & Iain Gardner. (2022) Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities. Xenobiotica 52:8, pages 840-854.
Read now
Read now
Articles from other publishers (59)
Daniela Silva Santurio, Emanuelle A. Paixão, Luciana R.C. Barros, Regina C. Almeida & Artur C. Fassoni. (2024) Mechanisms of resistance to CAR-T cell immunotherapy: Insights from a mathematical model. Applied Mathematical Modelling 125, pages 1-15.
Crossref
Crossref
Vardges Tserunyan & Stacey Finley. (2023) Information-Theoretic Analysis of a Model of CAR-4-1BB-Mediated NFκB Activation. Bulletin of Mathematical Biology 86:1.
Crossref
Crossref
Siak‐Leng Choi, Delphine Valente, Angela Virone‐Oddos & Christine Mauriac. (2023) Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first‐in‐human dose for acute myeloid leukemia. Clinical and Translational Science.
Crossref
Crossref
Faezeh Ramezani, Ahmad Reza Panahi Meymandi, Behnia Akbari, Omid Reza Tamtaji, Hamed Mirzaei, Christine E. Brown & Hamid Reza Mirzaei. (2023) Outsmarting trogocytosis to boost CAR NK/T cell therapy. Molecular Cancer 22:1.
Crossref
Crossref
Gianna M. Branella, Jasmine Y. Lee, Jennifer Okalova, Kiran K. Parwani, Jordan S. Alexander, Raquel F. Arthuzo, Andrew Fedanov, Bing Yu, David McCarty, Harrison C. Brown, Shanmuganathan Chandrakasan, Brian G. Petrich, Christopher B. Doering & H. Trent Spencer. (2023) Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia. Frontiers in Immunology 14.
Crossref
Crossref
Daniel C. Kirouac, Cole Zmurchok, Avisek Deyati, Jordan Sicherman, Chris Bond & Peter W. Zandstra. (2023) Deconvolution of clinical variance in CAR-T cell pharmacology and response. Nature Biotechnology 41:11, pages 1606-1617.
Crossref
Crossref
Anna M. Mc Laughlin, Peter A. Milligan, Cassian Yee & Martin Bergstrand. (2023)
Model‐informed drug development of autologous
CAR‐T
cell therapy: Strategies to optimize
CAR‐T
cell exposure leveraging cell kinetic/dynamic modeling
. CPT: Pharmacometrics & Systems Pharmacology 12:11, pages 1577-1590.
Crossref
Crossref
Mary P Choules, Peter L. Bonate, Nakyo Heo & Jared Weddell. (2023) Prospective approaches to gene therapy computational modeling – spotlight on viral gene therapy. Journal of Pharmacokinetics and Pharmacodynamics.
Crossref
Crossref
Harshana Rajakaruna, Milie Desai & Jayajit Das. (2023) PASCAR: a multiscale framework to explore the design space of constitutive and inducible CAR T cells. Life Science Alliance 6:10, pages e202302171.
Crossref
Crossref
Archana Mishra, Rituparna Maiti, Prafull Mohan & Pooja Gupta. (2023)
Antigen loss following
CAR‐T
cell therapy: Mechanisms, implications, and potential solutions
. European Journal of Haematology.
Crossref
Crossref
Jinwei Zhu, Yicui Zhang, Yixin Zhao, Jingwei Zhang, Kun Hao & Hua He. (2023) Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer. Pharmaceutics 15:9, pages 2274.
Crossref
Crossref
Vardges Tserunyan & Stacey D. Finley. (2023) A systems and computational biology perspective on advancing CAR therapy. Seminars in Cancer Biology 94, pages 34-49.
Crossref
Crossref
Hardik Mody, Ken Ogasawara, Xu Zhu, Dale Miles, Prathap Nagaraja Shastri, Jochem Gokemeijer, Michael Z. Liao, Sreeneeranj Kasichayanula, Tong‐Yuan Yang, Nagendra Chemuturi, Swati Gupta, Vibha Jawa & Vijay V. Upreti. (2023) Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective. Clinical Pharmacology & Therapeutics 114:3, pages 530-557.
Crossref
Crossref
Marissa Renardy, Alexander J. Prokopienko, Joseph R. Maxwell, Deborah A. Flusberg, Sahak Makaryan, Jangir Selimkhanov, Majid Vakilynejad, Kalyanasundaram Subramanian & Lucia Wille. (2023) A Quantitative Systems Pharmacology Model Describing the Cellular Kinetic‐Pharmacodynamic Relationship for a Live Biotherapeutic Product to Support Microbiome Drug Development. Clinical Pharmacology & Therapeutics 114:3, pages 633-643.
Crossref
Crossref
Ahmed M. Salem, Ganesh M. Mugundu & Aman P. Singh. (2023)
Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of
CAR T‐
cell subsets and immunophenotypes in cancer patients
. CPT: Pharmacometrics & Systems Pharmacology.
Crossref
Crossref
Ana Ruiz-Garcia, Paul Baverel, Dean Bottino, Michael Dolton, Yan Feng, Ignacio González-García, Jaeyeon Kim, Seth Robey, Indrajeet Singh, David Turner, Shu-Pei Wu, Donghua Yin, Di Zhou, Hao Zhu & Peter Bonate. (2023) A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. Journal of Pharmacokinetics and Pharmacodynamics 50:3, pages 147-172.
Crossref
Crossref
Ilaria M. Michelozzi, Eduardo Gomez-Castaneda, Ruben V. C. Pohle, Ferran Cardoso Rodriguez, Jahangir Sufi, Pau Puigdevall Costa, Meera Subramaniyam, Efstratios Kirtsios, Ayad Eddaoudi, Si Wei Wu, Aleks Guvenel, Jonathan Fisher, Sara Ghorashian, Martin A. Pule, Christopher J. Tape, Sergi Castellano, Persis J. Amrolia & Alice Giustacchini. (2023) Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. Blood Advances 7:9, pages 1725-1738.
Crossref
Crossref
Yoram Vodovotz. (2023) Towards systems immunology of critical illness at scale: from single cell ‘omics to digital twins. Trends in Immunology 44:5, pages 345-355.
Crossref
Crossref
Hideki Goto. (2023) Mechanisms and Clinical Features of Relapse and/or Refractory to CAR T-cell TherapyCD19標的CAR-T細胞療法における再発・治療抵抗性のメカニズムと臨床的特徴. Japanese Journal of Transplantation and Cellular Therapy 12:3, pages 172-180.
Crossref
Crossref
Tsukasa Seya, Megumi Tatematsu & Misako Matsumoto. (2022) Toward Establishing an Ideal Adjuvant for Non-Inflammatory Immune Enhancement. Cells 11:24, pages 4006.
Crossref
Crossref
Lunan Liu, Chao Ma, Zhuoyu Zhang, Matthew T Witkowski, Iannis Aifantis, Saba Ghassemi & Weiqiang Chen. (2022) Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. Journal for ImmunoTherapy of Cancer 10:12, pages e005360.
Crossref
Crossref
Thibaud Derippe, Sylvain Fouliard, Ibtissam Marchiq, Sandra Dupouy, Maria Almena-Carrasco, Julia Geronimi, Xavier Declèves, Marylore Chenel & Donald E. Mager. (2022) Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia. Cancer Research Communications 2:11, pages 1532-1544.
Crossref
Crossref
Emanuelle A. Paixão, Luciana R. C. Barros, Artur C. Fassoni & Regina C. Almeida. (2022) Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic Differentiation. Cancers 14:22, pages 5576.
Crossref
Crossref
Weize Huang, Junyi Li, Michael Z. Liao, Stephanie N. Liu, Jiajie Yu, Jing Jing, Naoki Kotani, Lynn Kamen, Sebastian Guelman & Dale R. Miles. (2022) Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology. Clinical Pharmacology & Therapeutics 112:5, pages 968-981.
Crossref
Crossref
Tina Giorgadze, Henning Fischel, Ansel Tessier & Kerri-Ann Norton. (2022) Investigating Two Modes of Cancer-Associated Antigen Heterogeneity in an Agent-Based Model of Chimeric Antigen Receptor T-Cell Therapy. Cells 11:19, pages 3165.
Crossref
Crossref
Feng Yu, Yang Gao, Yan Wu, Anran Dai, Xiaoyan Wang, Xiangzhi Zhang, Guodong Liu, Qinggang Xu & Dongfeng Chen. (2022) Combination of a Novel Fusion Protein CD3εζ28 and Bispecific T Cell Engager Enhances the Persistance and Anti-Cancer Effects of T Cells. Cancers 14:19, pages 4947.
Crossref
Crossref
Liam V. Brown, Mark C. Coles, Mark McConnell, Alexander V. Ratushny & Eamonn A. Gaffney. (2022) Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable. Journal of Pharmacokinetics and Pharmacodynamics 49:5, pages 539-556.
Crossref
Crossref
Chia-Hung Tsai, Aman P. Singh, Cindy Q. Xia & Haiqing Wang. (2022) Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice. Journal of Pharmacokinetics and Pharmacodynamics 49:5, pages 525-538.
Crossref
Crossref
Johannes Kast, Saeideh Nozohouri, Di Zhou, Marc R. Yago, Po‐Wei Chen, Malidi Ahamadi, Sandeep Dutta & Vijay V. Upreti. (2022) Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development. Clinical and Translational Science 15:9, pages 2057-2074.
Crossref
Crossref
Timothy Qi, Kyle McGrath, Raghuveer Ranganathan, Gianpietro Dotti & Yanguang Cao. (2022) Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. Advanced Drug Delivery Reviews 188, pages 114421.
Crossref
Crossref
Sreeneeranj Kasichayanula, Sandhya Mandlekar, Vittal Shivva, Maulik Patel & Sandhya Girish. (2022) Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy. Clinical and Translational Science 15:8, pages 1818-1837.
Crossref
Crossref
Muthuganesh Muthuvel, Harshita Srinivasan, Leena Louis & Sunil Martin. (2022) Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud. Cytokine 156, pages 155920.
Crossref
Crossref
Jae Yoon Jeon, Vivaswath S. Ayyar & Amitava Mitra. (2022) Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics – a Minireview. Pharmaceutical Research 39:8, pages 1749-1759.
Crossref
Crossref
Michael L. Olson, Erica R. Vander Mause, Sabarinath V. Radhakrishnan, Joshua D. Brody, Aaron P. Rapoport, Alana L. Welm, Djordje Atanackovic & Tim Luetkens. (2022) Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia 36:7, pages 1943-1946.
Crossref
Crossref
Gregory M. Chen, Jan Joseph Melenhorst & Kai Tan. (2022) B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?. Science Translational Medicine 14:650.
Crossref
Crossref
Yurong Lai, Xiaoyan Chu, Li Di, Wei Gao, Yingying Guo, Xingrong Liu, Chuang Lu, Jialin Mao, Hong Shen, Huaping Tang, Cindy Q. Xia, Lei Zhang & Xinxin Ding. (2022) Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharmaceutica Sinica B 12:6, pages 2751-2777.
Crossref
Crossref
Isabel Figueroa, Anika Gupta & Asin Peighambari. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
13
.
Camille Lenoir, Amine Niederer, Victoria Rollason, Jules Alexandre Desmeules, Youssef Daali & Caroline Flora Samer. (2021) Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. CPT: Pharmacometrics & Systems Pharmacology 11:1, pages 30-43.
Crossref
Crossref
Henning Fischel, Tina Giorgadze, Ansel Tessier & Kerri-Ann Norton. (2021) Computational Modeling of Chimeric Antigen Receptor (CAR) T-Cell Therapy of a Binary Model of Antigen Receptors in Breast Cancer. Computational Modeling of Chimeric Antigen Receptor (CAR) T-Cell Therapy of a Binary Model of Antigen Receptors in Breast Cancer.
Arthur J. Van De Vyver, Estelle Marrer-Berger, Ken Wang, Thorsten Lehr & Antje-Christine Walz. (2021) Cytokine Release Syndrome By T-cell–Redirecting Therapies: Can We Predict and Modulate Patient Risk?. Clinical Cancer Research 27:22, pages 6083-6094.
Crossref
Crossref
Bu-Fan Xiao, Jing-Tao Zhang, Yu-Ge Zhu, Xin-Run Cui, Zhe-Ming Lu, Ben-Tong Yu & Nan Wu. (2021) Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Frontiers in Immunology 12.
Crossref
Crossref
Vivaswath S. Ayyar, Dawei Song, Songmao Zheng, Thomas Carpenter & Donald L. Heald. (2021)
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
N
-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
. Journal of Pharmacology and Experimental Therapeutics 379:2, pages 134-146.
Crossref
Crossref
Aleksandra E. Kmieciak, Liam V. Brown, Mark C. Coles, Jonathan Wagg, Alex Phipps & Eamonn A. Gaffney. (2021) Predicted limited redistribution of T cells to secondary lymphoid tissue correlates with increased risk of haematological malignancies in asplenic patients. Scientific Reports 11:1.
Crossref
Crossref
Qiong Wu, Yan Wang, Xinyu Wang, Ningxia Liang, Jingjing Liu, Donghui Pan, Yuping Xu, Lizhen Wang, Junjie Yan, Guangji Wang, Liyan Miao & Min Yang. (2021) Pharmacokinetic and pharmacodynamic studies of CD19 CAR T cell in human leukaemic xenograft models with dual‐modality imaging. Journal of Cellular and Molecular Medicine 25:15, pages 7451-7461.
Crossref
Crossref
Shangzhi Xu, Xinyu Ge, Liuyang Wang, Yimin Tao, Dongmei Tang, Xiaojie Deng, Fei Yang, Qian Zhang, Xinming Qi, Likun Gong & Liming Yang. (2021) Profiling pharmacokinetics of double‐negative T cells and cytokines via a single intravenous administration in NSG mice. Biopharmaceutics & Drug Disposition 42:7, pages 338-347.
Crossref
Crossref
Anna Mueller-Schoell, Nahum Puebla-Osorio, Robin Michelet, Michael R. Green, Annette Künkele, Wilhelm Huisinga, Paolo Strati, Beth Chasen, Sattva S. Neelapu, Cassian Yee & Charlotte Kloft. (2021) Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers 13:11, pages 2782.
Crossref
Crossref
Zhengying Zhou, Jinwei Zhu, Muhan Jiang, Lan Sang, Kun Hao & Hua He. (2021) The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development. Pharmaceutics 13:5, pages 704.
Crossref
Crossref
Ujwani Nukala, Marisabel Rodriguez Messan, Osman N. Yogurtcu, Xiaofei Wang & Hong Yang. (2021) A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy. The AAPS Journal 23:3.
Crossref
Crossref
Aman P. Singh, Wenbo Chen, Xirong Zheng, Hardik Mody, Thomas J. Carpenter, Alice Zong & Donald L. Heald. (2021) Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T. CPT: Pharmacometrics & Systems Pharmacology 10:4, pages 362-376.
Crossref
Crossref
Can Liu, Vivaswath S. Ayyar, Xirong Zheng, Wenbo Chen, Songmao Zheng, Hardik Mody, Weirong Wang, Donald Heald, Aman P. Singh & Yanguang Cao. (2020) Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor‐T Cells in Humans. Clinical Pharmacology & Therapeutics 109:3, pages 716-727.
Crossref
Crossref
Shen Cheng, Susheel Kumar Nethi, Mahmoud Al-Kofahi & Swayam Prabha. (2021) Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells. Pharmaceutics 13:1, pages 92.
Crossref
Crossref
Tong-yuan Yang & Rajitha Doddareddy. (2021) Considerations in the development and validation of real-time quantitative polymerase chain reaction and its application in regulated bioanalysis to characterize the cellular kinetics of CAR-T products in clinical studies. Bioanalysis 13:2, pages 115-128.
Crossref
Crossref
Peter N. Morcos, Junyi Li, Iraj Hosseini & Chi‐Chung Li. (2020) Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities. Clinical and Translational Science 14:1, pages 75-85.
Crossref
Crossref
Damijan Valentinuzzi & Robert Jeraj. (2020) Computational modelling of modern cancer immunotherapy. Physics in Medicine & Biology 65:24, pages 24TR01.
Crossref
Crossref
Natalie Dullerud & Vanessa D. Jonsson. (2020) Cellular Immunotherapy Treatment Scheduling to Address Antigen Escape. Cellular Immunotherapy Treatment Scheduling to Address Antigen Escape.
John P. Gibbs, Theresa Yuraszeck, Carla Biesdorf, Yang Xu & Sreeneeranj Kasichayanula. (2020) Informing Development of Bispecific Antibodies Using Physiologically Based Pharmacokinetic‐Pharmacodynamic Models: Current Capabilities and Future Opportunities. The Journal of Clinical Pharmacology 60:S1.
Crossref
Crossref
Anwesha Chaudhury, Xu Zhu, Lulu Chu, Ardeshir Goliaei, Carl H. June, Jeffrey D. Kearns & Andrew M. Stein. (2020) Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic‐Pharmacodynamic Modeling Approaches. The Journal of Clinical Pharmacology 60:S1.
Crossref
Crossref
Na Li, Jiani Yuan, Wenjia Tian, Lin Meng & Yongyu Liu. (2020) T‐cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications. Cancer Communications 40:10, pages 473-483.
Crossref
Crossref
James W.T. Yates, Helen Byrne, Sonya C. Chapman, Tao Chen, Lourdes Cucurull‐Sanchez, Juan Delgado‐SanMartin, Giovanni Di Veroli, Simon J. Dovedi, Carina Dunlop, Rajesh Jena, Duncan Jodrell, Emma Martin, Francois Mercier, Antonio Ramos‐Montoya, Herbert Struemper & Paolo Vicini. (2020) Opportunities for Quantitative Translational Modeling in Oncology. Clinical Pharmacology & Therapeutics 108:3, pages 447-457.
Crossref
Crossref